Notification has no immediate effect on the Company’s listing or day-to-day operationsROSELAND, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Milestone…
Greater than 90% depletion of B cells within 12 hours of a single dose of AAN-14xMultiple redosing of AAN-14x at…
– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst’s HAE…
Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17,…
Cystic Fibrosis Foundation to provide up to $11 million in additional funding to accelerate development of 4D-710 for cystic fibrosis,…
Appointment adds three decades of financial and operational leadership to Soleno’s BoardREDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) --…
CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the…
Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 30…
While immune checkpoint inhibitors (anti-PD-1 +/- anti-CTLA-4) are approved as first line treatment for microsatellite instability-high (MSI-H) metastatic colorectal cancer…
New Black Book Research survey reveals Brazil, Mexico, Chile, and Colombia leading rapid adoption of openEHR frameworks as Doug Brown…